At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 225 enrolled
Drug / intervention
OTT166 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
In Brief
A Phase 2 clinical trial evaluating OTT166 and Vehicle control for Diabetic Retinopathy. Completed, enrolled 225 participants across 68 sites in 2 countries.
Detailed Summary
This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Retinopathy
CountriesPuerto Rico, United States
CollaboratorsParexel
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartJul 2022
Primary CompletionDec 2023
TodayJul 2026
First PostedJun 8, 2022
Enrollment StartJul 29, 2022
Primary CompletionDec 29, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.1 years ago
Interventions
OTT166drug
Participants will receive OTT166 ophthalmic solution
Vehicle controldrug
Participants will receive vehicle control